Despite thrombocytopenia, patients with sepsis often experience hypercoagulability. However, limited information is available on the prevalence and effect of hypercoagulability in patients with sepsis-induced thrombocytopenia. Hence, we evaluated the prevalence of hypercoagulability and the association between hypercoagulability and clinical outcomes in septic shock patients with thrombocytopenia.
Methods:
Thromboelastography (TEG) was performed prospectively in 1294 patients with septic shock at the emergency department (ED) between January 2016 and December 2019. After excluding 405 patients who did not require resuscitation, refused enrollment, or developed septic shock after ED presentation, 889 patients were included. We defined thrombocytopenia as an admission platelet count lower than 150,000/µl according to SOFA score. We defined hypocoagulability and hypercoagulability as coagulation index (CI)< −3 and >3 on TEG, respectively.
Results:
Of the 889 septic shock patients (mean age 65.6 ± 12.7 years, 58.6% male), 473 (53.2%) had thrombocytopenia. Eighty-five (18.0%) patients showed hypercoagulable TEG and73 (15.4%) patients showed hypocoagulable TEG. The hypercoagulable TEG group had a significantly higher fibrinogen level and a lower 28-day mortality rate than the normal and hypocoagulable TEG groups (518 vs. 347 and 315 mg/dL; 7.1% vs. 21.1% and 36.8%, P < 0.01, respectively). In multivariate analysis, hypercoagulable TEG was associated with a decreased mortality rate (odds ratio: 0.395; 95% confidence interval, 0.162-0.965).
Conclusions:
In septic shock patients with thrombocytopenia, hypercoagulability was not uncommon. TEG can quickly distinguish the hypercoagulability and hypocoagulability states and serve as a valuable tool for evaluating the degree and risk in septic shock patients with thrombocytopenia.
KinasewitzGTYanSBBassonB, et al.Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care. 2004;8(2):R82–90. doi:10.1186/cc2459
2.
AmaralAOpalSMVincentJL. Coagulation in sepsis. Intensive Care Med. 2004;30(6):1032–1040. doi:10.1007/s00134-004-2291-8
VincentJLMorenoRTakalaJ, et al.The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707–710. doi:10.1007/bf01709751
5.
MüllerMCMeijersJCVroomMBJuffermansNP. Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review. Crit Care. 2014;18(1):R30. doi:10.1186/cc13721
6.
ReikvamHSteienEHaugeB, et al.Thrombelastography. Transfus Apher Sci. 2009;40(2):119–123. doi:10.1016/j.transci.2009.01.019
7.
HinckerAFeitJSladenRNWagenerG. Rotational thromboelastometry predicts thromboembolic complications after major non-cardiac surgery. Crit Care. 2014;18(5):549. doi:10.1186/s13054-014-0549-2
8.
ToukhMSiemensDRBlackA, et al.Thromboelastography identifies hypercoagulablilty and predicts thromboembolic complications in patients with prostate cancer. Thromb Res. 2014;133(1):88–95. doi:10.1016/j.thromres.2013.10.007
9.
McCrathDJCerboniEFrumentoRJHirshALBennett-GuerreroE. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg. 2005;100(6):1576–1583. doi:10.1213/01.Ane.0000155290.86795.12
10.
HaaseNOstrowskiSRWetterslevJ, et al.Thromboelastography in patients with severe sepsis: a prospective cohort study. Intensive Care Med. 2015;41(1):77–85. doi:10.1007/s00134-014-3552-9
11.
JohanssonPIStensballeJVindeløvNPernerAEspersenK. Hypocoagulability, as evaluated by thrombelastography, at admission to the ICU is associated with increased 30-day mortality. Blood Coagul Fibrinolysis. 2010;21(2):168–174. doi:10.1097/MBC.0b013e3283367882
12.
KimYJKangJRyooSMAhnSHuhJWKimWY. Platelet-lymphocyte ratio after granulocyte colony stimulating factor administration: an early prognostic marker in septic shock patients with chemotherapy-induced febrile neutropenia. Shock. 2019;52(2):160–165. doi:10.1097/shk.0000000000001256
13.
DellingerRPLevyMMRhodesA, et al.Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228. doi:10.1007/s00134-012-2769-8
14.
CasserlyBPhillipsGSSchorrC, et al.Lactate measurements in sepsis-induced tissue hypoperfusion: results from the surviving sepsis campaign database. Crit Care Med. 2015;43(3):567–573. doi:10.1097/ccm.0000000000000742
15.
VincentJLde MendonçaACantraineF, et al.Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med.1998;26(11):1793–1800. doi:10.1097/00003246-199811000-00016
16.
GoldenbergNAHathawayWEJacobsonLManco-JohnsonMJ. A new global assay of coagulation and fibrinolysis. Thromb Res. 2005;116(4):345–356. doi:10.1016/j.thromres.2004.12.009
17.
LiuCGuanZXuQZhaoLSongYWangH. Relation of thromboelastography parameters to conventional coagulation tests used to evaluate the hypercoagulable state of aged fracture patients. Medicine (Baltimore). 2016;95(24):e3934. doi:10.1097/md.0000000000003934
18.
LeviMPollT. Coagulation in patients with severe sepsis. Semin Thromb Hemost. 2015;41(1):9–15. doi:10.1055/s-0034-1398376
19.
AngusDCvan der PollT. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840–851. doi:10.1056/NEJMra1208623
20.
LeviM. The coagulant response in sepsis and inflammation. Hamostaseologie. 2010;30(1):10–12, 14–16.
21.
OstrowskiSRWindeløvNAIbsenMHaaseNPernerAJohanssonPI. Consecutive thrombelastography clot strength profiles in patients with severe sepsis and their association with 28-day mortality: a prospective study. J Crit Care. 2013;28(3):317.e1–11. doi:10.1016/j.jcrc.2012.09.003
22.
DrewsREWeinbergerSE. Thrombocytopenic disorders in critically ill patients. Am J Respir Crit Care Med. 2000;162(2 Pt 1):347–351. doi:10.1164/ajrccm.162.2.ncc3-00
23.
VenkataCKashyapRFarmerJCAfessaB. Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcome. J Intensive Care. 2013;1(1):9. doi:10.1186/2052-0492-1-9
24.
SharmaBSharmaMMajumderMSteierWSangalAKalawarM. Thrombocytopenia in septic shock patients—a prospective observational study of incidence, risk factors and correlation with clinical outcome. Anaesth Intensive Care. 2007;35(6):874–880. doi:10.1177/0310057x0703500604
25.
VandijckDMBlotSIDe WaeleJJHosteEAVandewoudeKHDecruyenaereJM. Thrombocytopenia and outcome in critically ill patients with bloodstream infection. Heart Lung. 2010;39(1):21–26. doi:10.1016/j.hrtlng.2009.07.005
26.
TsirigotisPChondropoulosSFrantzeskakiF, et al.Thrombocytopenia in critically ill patients with severe sepsis/septic shock: prognostic value and association with a distinct serum cytokine profile. J Crit Care. 2016;32:9–15. doi:10.1016/j.jcrc.2015.11.010
27.
AdamikBGozdzikWJakubczykDWelnaMKüblerA. Coagulation abnormalities identified by thromboelastometry in patients with severe sepsis: the relationship to endotoxemia and mortality. Blood Coagul Fibrinolysis. 2017;28(2):163–170. doi:10.1097/mbc.0000000000000572
28.
MassionPBPetersPLedouxD, et al.Persistent hypocoagulability in patients with septic shock predicts greater hospital mortality: impact of impaired thrombin generation. Intensive Care Med. 2012;38(8):1326–1335. doi:10.1007/s00134-012-2620-2
29.
EngelmannBMassbergS. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34–45. doi:10.1038/nri3345
30.
WarrenBLEidASingerP, et al.Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286(15):1869–1878. doi:10.1001/jama.286.15.1869
31.
VincentJLFrancoisBZabolotskikhI, et al.Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial. Jama. 2019;321(20):1993–2002. doi:10.1001/jama.2019.5358
32.
RanieriVMThompsonBTBariePS, et al.Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055–2064. doi:10.1056/NEJMoa1202290
33.
IbaTLevyJHRajAWarkentinTE. Advance in the management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Clin Med. 2019;8(5):728. doi:10.3390/jcm8050728
34.
UmemuraYYamakawaK. Optimal patient selection for anticoagulant therapy in sepsis: an evidence-based proposal from Japan. J Thromb Haemost. 2018;16(3):462–464. doi:10.1111/jth.13946
